Adherence to Protease Inhibitors
Authors: Rita Murri, Adriana Ammassari, Andrea Antinori
Journal: Annals of Internal Medicine (2001)

Letters3 April 2001Adherence to Protease InhibitorsRita Murri, MD, Adriana Ammassari, MD, and Andrea Antinori, MDRita Murri, MDCatholic University; 00168 Rome, Italy (Murri, Ammassari)National Institute for Infectious Diseases, "L. Spallanzani"; 00149 Rome, Italy (Antinori), Adriana Ammassari, MDCatholic University; 00168 Rome, Italy (Murri, Ammassari)National Institute for Infectious Diseases, "L. Spallanzani"; 00149 Rome, Italy (Antinori), and Andrea Antinori, MDCatholic University; 00168 Rome, Italy (Murri, Ammassari)National Institute for Infectious Diseases, "L. Spallanzani"; 00149 Rome, Italy (Antinori)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-7-200104030-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In an excellent paper, Paterson and colleagues (1) demonstrate that adherence to protease inhibitor therapy of 95% or greater optimizes virologic outcome for patients with HIV infection. In our opinion, however, this conclusion cannot be generalized to all HIV-infected patients, especially those who were previously treated with antiretroviral agents.We performed a prospective cohort study on adherence to antiretroviral agents in 140 consecutive HIV-infected patients who were attending the outpatient service of the Department of Infectious Diseases, Catholic University of Rome, Rome, Italy, and were taking a regimen containing protease inhibitors. Median duration of antiretroviral therapy was ...References1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al . Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. [PMID: 0010877736] LinkGoogle Scholar2. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, et al . Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr. 2000;24:123-8. [PMID: 0010935687] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Catholic University; 00168 Rome, Italy (Murri, Ammassari)National Institute for Infectious Diseases, "L. Spallanzani"; 00149 Rome, Italy (Antinori) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAdherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection David L. Paterson , Susan Swindells , Jeffrey Mohr , Michelle Brester , Emanuel N. Vergis , Cheryl Squier , Marilyn M. Wagener , and Nina Singh Adherence to Protease Inhibitors David L. Paterson and Nina Singh Metrics Cited ByImpact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy'The Head that Doesn't Speak One Calls a Cabbage:' Hiv, Aids, Risk, and Social Support in the 21St Century 3 April 2001Volume 134, Issue 7Page: 625KeywordsAntiretroviral therapyAntiretroviralsHIVHIV infectionsInfectious diseasesOdds ratioOutpatientsProtease inhibitor therapyProtease inhibitorsRNA ePublished: 3 April 2001 Issue Published: 3 April 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...